[{"id":"c4c82fe3-fb0f-463e-9f2b-c75e3ed45026","acronym":"","url":"https://clinicaltrials.gov/study/NCT01175343","created_at":"2021-01-18T04:41:25.819Z","updated_at":"2024-07-02T16:37:21.804Z","phase":"Phase 2","brief_title":"RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT01175343","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG4733"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2017-05-24"}]